G3BP2 and breast carcinoma: To analyze whether the effect on PMP22 mRNA is seen in other breast cancer cells as well, three additional cell lines (MDA-MB-231, MDA-MB-468 and BT549) were treated with siRNAs targeting G3BP1 and/or G3BP2 (Figure 3C-E).